With the growing incidence of obesity-related malignancies,glucagon-like peptide-1(GLP-1)receptor agonists represent an intriguing potential clinical avenue for cancer prevention and treatment.Population-based data su...With the growing incidence of obesity-related malignancies,glucagon-like peptide-1(GLP-1)receptor agonists represent an intriguing potential clinical avenue for cancer prevention and treatment.Population-based data suggest that individuals who have taken GLP-1 receptor agonists have a decreased incidence of obesity-related cancers.Moreover,in vivo and in vitro studies have demonstrated the antitumor activity of these agents independent of other antineoplastic therapeutics.Additionally,other pre-clinical studies have shown that GLP-1 receptor agonists may help overcome resistance to chemotherapy-refractory cancer cells,thus demonstrating a plausible role in cancer treatment.Randomized controlled trials utilizing GLP-1 receptor agonists in both cancer prevention and treatment may allow for a better understanding of the role of these agents in modern oncology.展开更多
文摘With the growing incidence of obesity-related malignancies,glucagon-like peptide-1(GLP-1)receptor agonists represent an intriguing potential clinical avenue for cancer prevention and treatment.Population-based data suggest that individuals who have taken GLP-1 receptor agonists have a decreased incidence of obesity-related cancers.Moreover,in vivo and in vitro studies have demonstrated the antitumor activity of these agents independent of other antineoplastic therapeutics.Additionally,other pre-clinical studies have shown that GLP-1 receptor agonists may help overcome resistance to chemotherapy-refractory cancer cells,thus demonstrating a plausible role in cancer treatment.Randomized controlled trials utilizing GLP-1 receptor agonists in both cancer prevention and treatment may allow for a better understanding of the role of these agents in modern oncology.
